New Jersey Assembly Bill A864

New Jersey 2026-2027 Regular Session

• Introduced: 1/13/26
• Refer: 1/13/26

Caption

Classifies xylazine as Schedule III controlled dangerous substance under certain circumstances.

Impact

The legislation seeks to amend existing laws governing controlled substances by adding xylazine to Schedule III, thereby subjecting it to regulations that apply to similarly classified drugs. This includes standard criminal penalties for illegal manufacturing, distribution, dispensing, possession, and use. The penalties for violating these regulations can lead to significant imprisonment terms and hefty fines, particularly for offenses occurring near schools or involving minors. By making xylazine a controlled substance, the state aims to reduce its illegal distribution and misuse, ultimately fostering a safer environment for residents.

Summary

Bill A864 proposes the classification of xylazine as a Schedule III controlled dangerous substance (CDS) under certain circumstances. Xylazine, commonly known by its street names 'tranq', 'tranq dope', and 'zombie drug', has gained notoriety for its presence in illicit drug mixtures, particularly in combination with opioids, where it can enhance the euphoric effects. However, xylazine does not respond to opioid antidotes like naloxone, contributing to a heightened risk of overdose. This bill aims to mitigate the public health crisis associated with this substance by imposing regulations on its use outside professional veterinary settings.

Contention

The bill's deliberations highlighted various points of contention among lawmakers and stakeholders. Supporters argue that regulating xylazine will protect public health and save lives by controlling a substance linked to increasing numbers of overdose cases. Conversely, critics may point out the need for a comprehensive approach to drug addiction that includes treatment and prevention strategies rather than solely punitive measures. The distinction between legal veterinary use and illicit human consumption remains a critical discussion point, raising questions about the enforcement of these regulations and the adequacy of existing resources for addiction treatment.